Vertex Pharmaceuticals Incorporated (VRTX) Position Lifted by Jefferies Group LLC

Jefferies Group LLC lifted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 103.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,686 shares of the pharmaceutical company’s stock after buying an additional 101,414 shares during the period. Jefferies Group LLC’s holdings in Vertex Pharmaceuticals were worth $710,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Stratos Wealth Partners LTD. purchased a new position in Vertex Pharmaceuticals during the 3rd quarter worth $123,000. Sun Life Financial INC grew its position in Vertex Pharmaceuticals by 266.1% during the 2nd quarter. Sun Life Financial INC now owns 692 shares of the pharmaceutical company’s stock worth $118,000 after purchasing an additional 503 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new position in Vertex Pharmaceuticals during the 2nd quarter worth $125,000. TRUE Private Wealth Advisors purchased a new position in Vertex Pharmaceuticals during the 3rd quarter worth $169,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in Vertex Pharmaceuticals during the 3rd quarter worth $170,000. 93.79% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:VRTX opened at $170.06 on Friday. The stock has a market capitalization of $44.32 billion, a PE ratio of 212.58, a PEG ratio of 1.72 and a beta of 1.65. The company has a current ratio of 3.71, a quick ratio of 3.59 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $142.05 and a fifty-two week high of $194.92.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Wednesday, October 24th. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.02 by $0.07. The business had revenue of $784.54 million for the quarter, compared to the consensus estimate of $782.95 million. Vertex Pharmaceuticals had a net margin of 22.87% and a return on equity of 22.92%. During the same quarter in the previous year, the firm earned $0.53 earnings per share. On average, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 2.55 earnings per share for the current fiscal year.

In related news, SVP Paul M. Silva sold 809 shares of the firm’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $186.52, for a total value of $150,894.68. Following the completion of the sale, the senior vice president now owns 16,896 shares in the company, valued at $3,151,441.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Thomas Graney sold 1,076 shares of the firm’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $193.24, for a total transaction of $207,926.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 28,346 shares of company stock worth $5,264,953. Insiders own 0.75% of the company’s stock.

Several research analysts have issued reports on the stock. Zacks Investment Research reissued a “buy” rating and set a $191.00 price objective on shares of Vertex Pharmaceuticals in a research report on Saturday, November 17th. Cantor Fitzgerald reissued a “buy” rating and set a $217.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, November 27th. BidaskClub raised shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, September 27th. BMO Capital Markets lowered their price objective on shares of Vertex Pharmaceuticals from $204.00 to $192.00 and set an “outperform” rating on the stock in a research report on Thursday, October 25th. Finally, Oppenheimer set a $200.00 price objective on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, November 27th. Three analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $202.38.

WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) Position Lifted by Jefferies Group LLC” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.com-unik.info/2018/12/16/vertex-pharmaceuticals-incorporated-vrtx-position-lifted-by-jefferies-group-llc.html.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor.

Featured Article: What is the float in trading stocks?

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit